No Denying It: Medicinal Chemistry Training Is in Big Trouble

Journal of Medicinal Chemistry

Volumn 59, Issue 24, 2016, Pages 10859-10864

  Rafferty, Michael F ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DESIGN; DRUG INDUSTRY; EXPERIENTIAL LEARNING; HUMAN; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICINAL CHEMISTRY; ORGANIZATION; REVIEW; SOLUTION AND SOLUBILITY; DRUG DEVELOPMENT; MOLECULAR LIBRARY;

MOLECULAR LIBRARY;

CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 85007228226     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00741     Document Type: Review

References (33)

1. Busse, W. D.; Ganellin, C. R.; Mitscher, L. A. Vocational training for medicinal chemists: views from industry Eur. J. Med. Chem. 1996, 31, 747-760 10.1016/0223-5234(96)83968-7
2. Ganellin, C. R.; Mitscher, L. A.; Clement, B.; Kobayashi, T.-H.; Kyburz, E.; Lafont, O.; Marcinal, A.; Monge, A.; Tarzia, G.; Topliss, J. G. University education of medicinal chemists: comparison of eight countries Eur. J. Med. Chem. 2000, 35, 163-174 10.1016/S0223-5234(00)00107-0
3. Frantz, S. Training academic chemists for industry Nat. Rev. Drug Discovery 2004, 3, 719 10.1038/nrd1483
4. Timmerman, H.; de Souza, N. J. Medicinal chemistry teaching and training: a continuous adaptation ChemMedChem 2009, 4, 1055-1058 10.1002/cmdc.200900128
5. Wess, G. Challenges for medicinal chemistry Drug Discovery Today 1996, 1, 529-532 10.1016/S1359-6446(96)10047-7
6. Krogsgaard-Larsen, P.; Pelliciari, R.; De Souza, N.; Timmerman, H.; Triggle, D. J.; van Boeckel, C. A. A.; Wasley, J. Medicinal chemistry education: what is needed and where is it going? Drug Dev. Res. 2005, 66, 1-8 10.1002/ddr.20038
7. Kolb, D. A.; Boyatzis, R. E.; Mainemelis, C. Experiential Learning Theory: Previous Research and New Directions. In Perspectives on Thinking, Learning, and Cognitive Styles; Sternberg, R. J.; Zhang, L. F., Eds.; Lawrence Erlbaum and Associates: Mahwah, NJ, 2000; pp 227-248.
8. Einhorn, H. J. Expert judgment: some necessary conditions and an example J. Appl. Psychol. 1974, 59, 562-571 10.1037/h0037164
9. Keseru, G. M.; Makara, G. M. Hit discovery and hit-to-lead approaches Drug Discovery Today 2006, 11, 741-748 10.1016/j.drudis.2006.06.016
10. Lajiness, M. S.; Maggiora, G. M.; Shanmugasundaram, V. Assessment of the consistency of medicinal chemists in reviewing sets of compounds J. Med. Chem. 2004, 47, 4891-4896 10.1021/jm049740z
11. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discovery 2009, 8, 203-212 10.1038/nrd2796
12. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A Rule of Three for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877 10.1016/S1359-6446(03)02831-9
13. Kutchukian, P. S.; Vasilyeva, N. Y.; Xu, J.; Lindvall, M. K.; Dillon, M. P.; Glick, M.; Coley, J. D.; Brooijmans, N. Inside the mind of a medicinal chemist: the role of human bias in compound prioritization during drug discovery PLoS One 2012, 7, e48476 10.1371/journal.pone.0048476
14. Leeson, P. D.; Young, R. J. Molecular property design: does everyone get it? ACS Med. Chem. Lett. 2015, 6, 722-725 10.1021/acsmedchemlett.5b00157
15. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
16. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
17. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discovery 2009, 8, 203-212 10.1038/nrd2796
18. Yan, A.; Gasteiger, J. Prediction of aqueous solubility of organic compounds by topological descriptors QSAR Comb. Sci. 2003, 22, 821-829 10.1002/qsar.200330822
19. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449 10.1021/cn100008c
20. Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the chemical beauty of drugs Nat. Chem. 2012, 4, 90-98 10.1038/nchem.1243
21. Cheshire, D. R. How well do medicinal chemists learn from experience? Drug Discovery Today 2011, 16, 817-821 10.1016/j.drudis.2011.06.005
22. Nussbaumer, P. Medicinal chemists of the 21st century-who are we and where to go? ChemMedChem 2015, 10, 1133-1139 10.1002/cmdc.201500133
23. Felts, A. S.; Rodriguez, A. L.; Smith, K. A.; Engers, J. L.; Morrison, R. D.; Byers, F. W.; Blobaum, A. L.; Locuson, C. W.; Chang, S.; Venable, D. F.; Niswender, C. M.; Daniels, J. S.; Conn, J.; Lindsley, C. W.; Emmitte, K. A. Design of 4-oxo-1-aryl-1,4-dihydroisoquinoline-3-carboxamides as selective negative allosteric modulators of metabotropic glutamate receptor subtype 2 J. Med. Chem. 2015, 58, 9027-9040 10.1021/acs.jmedchem.5b01371
24. Hann, M. M. Molecular obesity, potency and other addictions in drug discovery MedChemComm 2011, 2, 349-355 10.1039/c1md00017a
25. Hann, M. M.; Keseru, G. M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discovery 2012, 11, 355-365 10.1038/nrd3701
26. Meanwell, N. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456 10.1021/tx200211v
27. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A Comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 2003, 46, 1250-1256 10.1021/jm021053p
28. Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
29. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Central nervous system multiparameter optimization desirability: application in drug discovery ACS Chem. Neurosci. 2016, 7, 767-775 10.1021/acschemneuro.6b00029
30. About IFD. http://innovationsfonden.dk/en/about-ifd (accessed August 1, 2016).
31. Research & Innovation. Marie Sklodowska-Curie Actions. http://ec.europa.eu/research/mariecurieactions/ (accessed August 1, 2016).
32. Innovative Medicines Initiative. https://www.imi.europa.eu (accessed August 1, 2016).
33. Grant Opportunities for Academic Liaison with Industry (GOALI). https://www.nsf.gov/funding/pgm-summ.jsp?pims-id=504699 (accessed August 1, 2016).